

DOCON TECHNOLOGIES PRIVATE LIMITED

November 11, 2025

To, National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400051	To, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400001
To, Thyrocare Technologies Limited D37/3, TTC MIDC, Turbhe, Navi Mumbai – 400073	

Sub: Update on the earlier submitted disclosures for creation of Pledge on 3,23,23,232 Shares of Thyrocare Technologies Limited (comprising 60.93% of the total share capital) of Thyrocare Technologies Limited (“Thyrocare”) by Docon Technologies Private Limited (“Docon”).

Dear Sir & Madam,

We refer to our earlier disclosure made on **September 24, 2025**, under Regulation 31 of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (“SEBI SAST Regulations”) in respect of the encumbrance created by **Docon Technologies Private Limited** (“Docon”), Promoter of **Thyrocare Technologies Limited** (“the Company”), in favour of **Catalyst Trusteeship Limited**, acting as Debenture Trustee for the Non-Convertible Debentures (“NCDs”) issued by **API Holdings Limited**, the holding company of Docon.

Please note that **API Holdings Limited** has fully repaid and redeemed the **Series 2 NCDs amounting to ₹500 crore on October 28, 2025**. However, there is **no change in the number of encumbered shares** of Thyrocare held by Docon. Certain other details previously disclosed on September 24, 2025, (such as promoter shareholding percentage and particulars of the debenture series) have been updated to reflect the current position.

The updated details are enclosed in Annexure 1 in the format prescribed under the Regulations 31 of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 as **Annexure I**.

You are requested to take the same on record

For and on behalf of Docon Technologies Private Limited



Madhuri Sudhir Sarangdhar
Company Secretary

Encl: **Annexure 1**

DOCON TECHNOLOGIES PRIVATE LIMITED

Annexure 1

Format for disclosure by the Promoter(s) to the stock exchanges and to the Target Company for encumbrance of shares / invocation of encumbrance/ release of encumbrance, in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 – Annexure I

Name of the Target Company (TC)					Thyrocare Technologies Limited (“Thyrocare”)								
Names of the stock exchanges where the shares of the target company are listed					1. BSE Limited 2. National Stock Exchange of India Limited								
Date of reporting					November 11, 2025								
Name of the promoter or PAC on whose shares encumbrance has been created/released/invoked					Promoter: Docon Technologies Private Limited PAC: API Holdings Limited								
Details of the creation of encumbrance													
Name of the promoter(s) or PACs with him*	Promoter holding in the target company (1)		Promoter holding already encumbered (2)		Details of events pertaining to encumbrance (3)							Post event holding of Encumbered shares {creation [(2)+(3)] / release [(2)-(3)] / invocation [(1)-(3)]}	
	Number	% of total share capital	Number	% of total share capital	Type of event (creation /Release / invocation)	Date of creation /release/ invocation of encumbrance	Type of encumbrance (pledge/line/ non disposal undertaking/ others)	Reasons for encumbrance **	Number	% of share capital	Name of the entity in whose favor shares Encumbered ***	Number	% of total share capital
Docon Technologies Private Limited (“Docon”)	3,23,23,232	60.93	3,23,23,232	60.93	Update on earlier intimation submitted with respect to Creation	On October 28, 2025, API Holdings Limited has	Others* *API Holdings Limited has fully repaid and redeemed the Series 2 NCDs amounting to	Docon has not created any fresh/new encumbrance on the shares of Thyrocare. The encumbrance on shares has been created pursuant to the Corporate Guarantee extended by Docon	3,23,23,232	60.93	The Shares has been pledged with Catalyst Trusteeship Limited as Debenture Trustee for Debenture issued by API. 12,000 (Twelve Thousand) unlisted, unrated, secured, redeemable non-convertible debentures of the face value of INR 10,00,000/- (Indian Rupees Ten Lakhs only)	3,23,23,232	60.93



DOCON TECHNOLOGIES PRIVATE LIMITED

					<p>of Pledge of shares</p> <p>redeemed /made payment of Series-2 Debentures; however, there is no change in the number of encumbered shares of Thyrocare as filed in our earlier disclosures dated September 24, 2025, to both the Stock Exchanges (NSE and BSE) and Thyrocare.</p>	<p>₹500 crore on October 28, 2025. However, there is no change in the number of encumbered shares of Thyrocare held by Docon. Certain other details previously disclosed (such as promoter shareholding percentage and particulars of the debenture series). Details of Series 2 Debentures which fully repaid and redeemed are provided in the Exhibit A</p>	<p>Technologies Private Limited ("Docon") to secure the obligations of API Holdings Limited ("API"), the Holding Company, in respect of facilities availed by API through issuance of unlisted, unrated, secured, redeemable, non-convertible debentures ("Facility").</p> <p>Accordingly, Docon has pledged 3,23,23,232 equity shares of Thyrocare (representing 60.93% of total share capital of Thyrocare) in favour of Catalyst Trusteeship Limited, acting as Debenture Trustee, as security for the aforesaid facility.</p> <p>API Holdings Limited has fully repaid and redeemed the Series 2 NCDs amounting to ₹500 crore on October 28, 2025. However, there is no change in the number of encumbered shares of Thyrocare held by</p>		<p>each at par, and aggregate nominal value of up to INR 12,000 million (Indian Rupees Twelve Thousand Million only) (" Series 1 Debenture") and</p> <p>Details of Debenture Holders/Investors for Series 1 Debenture:</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 5%;">Sr</th> <th style="width: 70%;">NAME</th> <th style="width: 25%;">Amount in Million</th> </tr> </thead> <tbody> <tr> <td>1</td> <td>360 ONE PRIME LIMITED</td> <td>3,921</td> </tr> <tr> <td>2</td> <td>MICRO LABS LIMITED</td> <td>2,068</td> </tr> <tr> <td>3</td> <td>360 ONE REAL ASSETS ADVANTAGE FUND</td> <td>1,330</td> </tr> <tr> <td>4</td> <td>360 ONE COMMERCIAL YIELD FUND</td> <td>900</td> </tr> <tr> <td>5</td> <td>MVS VENTURES PRIVATE LIMITED</td> <td>737</td> </tr> <tr> <td>6</td> <td>BENNETT COLEMAN AND COMPANY LIMITED</td> <td>500</td> </tr> <tr> <td>7</td> <td>ALKRAM VENTURE PRIVATE LIMITED</td> <td>397</td> </tr> <tr> <td>8</td> <td>360 ONE INCOME OPPORTUNITIES FUND - SERIES 3</td> <td>340</td> </tr> <tr> <td>9</td> <td>360 ONE INCOME OPPORTUNITIES FUND - SERIES 6</td> <td>340</td> </tr> </tbody> </table>	Sr	NAME	Amount in Million	1	360 ONE PRIME LIMITED	3,921	2	MICRO LABS LIMITED	2,068	3	360 ONE REAL ASSETS ADVANTAGE FUND	1,330	4	360 ONE COMMERCIAL YIELD FUND	900	5	MVS VENTURES PRIVATE LIMITED	737	6	BENNETT COLEMAN AND COMPANY LIMITED	500	7	ALKRAM VENTURE PRIVATE LIMITED	397	8	360 ONE INCOME OPPORTUNITIES FUND - SERIES 3	340	9	360 ONE INCOME OPPORTUNITIES FUND - SERIES 6	340	
Sr	NAME	Amount in Million																																						
1	360 ONE PRIME LIMITED	3,921																																						
2	MICRO LABS LIMITED	2,068																																						
3	360 ONE REAL ASSETS ADVANTAGE FUND	1,330																																						
4	360 ONE COMMERCIAL YIELD FUND	900																																						
5	MVS VENTURES PRIVATE LIMITED	737																																						
6	BENNETT COLEMAN AND COMPANY LIMITED	500																																						
7	ALKRAM VENTURE PRIVATE LIMITED	397																																						
8	360 ONE INCOME OPPORTUNITIES FUND - SERIES 3	340																																						
9	360 ONE INCOME OPPORTUNITIES FUND - SERIES 6	340																																						

DOCON TECHNOLOGIES PRIVATE LIMITED

												Total	12,000			

For and on behalf of Docon Technologies Private Limited



Madhuri Sudhir Saranghar
Company Secretary
Membership no. A36893

Date: November 11, 2025

(**) The names of all the promoters, their shareholding in the target company and their pledged shareholding as on the reporting date should appear in the table irrespective of whether they are reporting on the date of event or not.

(*) Total share capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement. Diluted share / voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities / warrants into equity shares of the TC.

DOCON TECHNOLOGIES PRIVATE LIMITED

Exhibit A

Details of Debenture Holders/Investors for Series 2 Debenture which has been paid entirely and redeemed are given below:

Sr	Name	Amt in Million
1	360 ONE PRIME LIMITED	2,498
2	360 ONE REAL ASSETS ADVANTAGE FUND	670
3	360 ONE COMMERCIAL YIELD FUND	450
4	KARAN BHAGAT	370
5	360 ONE INCOME OPPORTUNITIES FUND - SERIES 3	160
6	360 ONE INCOME OPPORTUNITIES FUND - SERIES 6	160
7	HEMA AHUJA	100
8	PRAKASH KUMAR GUHA	83
9	360 ONE INCOME OPPORTUNITIES FUND - SERIES 7	50
10	RAJENDRAKUMAR SHIVKISHAN AGRAWAL	50
11	MVS VENTURES PRIVATE LIMITED	43
12	360 ONE LARGE VALUE FUND - SERIES 2	35
13	MICRO LABS LIMITED	34
14	DAYANIDHI MARAN	34
15	HORIZON IMPEX PRIVATE LIMITED	25
16	ALKRAM VENTURE PRIVATE LIMITED	23
17	WARMOND FIDUCIARY SERVICES LIMITED	20
18	ADVIK HI TECH PRIVATE LIMITED	17
19	LAKE CHEMICALS P LTD	17
20	VARA FUTURE LLP	17
21	MEDLEY PHARMACEUTICALS LIMITED	17
22	TERITEX KNITTING INDUSTRIES PRIVATE LIMITED	17
23	PITRE BUSINESS VENTURES LLP	17
24	WARMOND FIDUCIARY SERVICES LIMITED	13
25	WARMOND FIDUCIARY SERVICES LIMITED	13
26	BAGLA INDUSTRIES PRIVATE LIMITED	12
27	WARMOND FIDUCIARY SERVICES LIMITED	10
28	WARMOND FIDUCIARY SERVICES LIMITED	10
29	JPM MERCHANDISE AGENCIES LIMITED	10
30	URMILA BEHERA	7
31	WARMOND FIDUCIARY SERVICES LIMITED	7
32	WARMOND FIDUCIARY SERVICES LIMITED	7
33	WARMOND FIDUCIARY SERVICES LIMITED	3
34	KYROGENIUS FITNESS TECHNOLOGY PRIVATE LIMITED	1
Total		5,000